Last reviewed · How we verify
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.
Details
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 22 |
| Start date | Sat Feb 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Aug 09 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Nasopharyngeal Carcinoma
Interventions
- Anti-PD1 antibody, nimotuzumab and capecitabine
Countries
China